Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price objective lowered by Citigroup from $26.00 to $20.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price objective suggests a potential upside of 228.41% from the stock’s previous close.
A number of other research analysts have also recently issued reports on CADL. Wall Street Zen cut shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Thursday, October 15th. HC Wainwright decreased their target price on Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Friday. Canaccord Genuity Group dropped their price target on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Jefferies Financial Group assumed coverage on Candel Therapeutics in a research report on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price objective for the company. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.29.
Check Out Our Latest Stock Analysis on Candel Therapeutics
Candel Therapeutics Price Performance
CADL stock traded down $0.11 during trading on Monday, hitting $6.09. The company had a trading volume of 1,996,615 shares, compared to its average volume of 1,451,537. The firm has a market capitalization of $466.00 million, a price-to-earnings ratio of -4.06 and a beta of -0.27. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average of $9.75 and a 200 day moving average of $8.39. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $14.00.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. As a group, research analysts predict that Candel Therapeutics will post -1.29 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in CADL. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Candel Therapeutics in the third quarter worth $41,000. Legal & General Group Plc purchased a new position in Candel Therapeutics in the 2nd quarter worth approximately $63,000. Cetera Investment Advisers purchased a new position in shares of Candel Therapeutics during the third quarter valued at approximately $124,000. Renaissance Technologies LLC purchased a new position in Candel Therapeutics in the first quarter worth about $63,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock worth $152,000 after acquiring an additional 2,301 shares during the period. 13.93% of the stock is owned by hedge funds and other institutional investors.
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
